Oryzon Genomics SA
MAD:ORY
Oryzon Genomics SA
Intangible Assets
Oryzon Genomics SA
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oryzon Genomics SA
MAD:ORY
|
Intangible Assets
€109.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
22%
|
|
|
Grifols SA
MAD:GRF
|
Intangible Assets
€2.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
9%
|
|
|
Pharma Mar SA
MAD:PHM
|
Intangible Assets
€3.5m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-18%
|
|
Oryzon Genomics SA
Glance View
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
See Also
What is Oryzon Genomics SA's Intangible Assets?
Intangible Assets
109.2m
EUR
Based on the financial report for Dec 31, 2025, Oryzon Genomics SA's Intangible Assets amounts to 109.2m EUR.
What is Oryzon Genomics SA's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
22%
Over the last year, the Intangible Assets growth was 11%. The average annual Intangible Assets growth rates for Oryzon Genomics SA have been 13% over the past three years , 17% over the past five years , and 22% over the past ten years .
